The DDI Manager Fungal Infections has been expanded with a new drug rezafungin.

It is approved by the FDA and EMA since March and December 2023, respectively. Rezafungin is indicated for the treatment of invasive candidiasis in adults. In the United States, rezafungin is also indicated for candidemia and only for use in patients with limited or no alternative options of treatment. The interaction profile is limited because metabolism do not involve enzymes. No effect of rezafungin was seen on enzymes during clinical studies.

See for more information the article about the clinical studies with several drugs (e.g. midazolam, ciclosporin, digoxin): Flanagan et al; 2023.